PD-L1 expression by IHC was approved by FDA as a diagnostic test for pembrolizumab in cancer treatment, including NSCLC, gastric or gastroesophageal junction adenocarcinoma, and urothelial carcinoma [23,24,25,26]. This evidence concerns the gene CD274 and urothelial carcinoma.